NASDAQ:TSHA Taysha Gene Therapies (TSHA) Stock Price, News & Analysis $2.42 +0.08 (+3.42%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$2.46 +0.04 (+1.69%) As of 08:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Taysha Gene Therapies Stock (NASDAQ:TSHA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Taysha Gene Therapies alerts:Sign Up Key Stats Today's Range$2.33▼$2.5050-Day Range$1.91▼$2.9352-Week Range$1.05▼$3.31Volume2.31 million shsAverage Volume2.91 million shsMarket Capitalization$519.48 millionP/E RatioN/ADividend YieldN/APrice Target$8.20Consensus RatingBuy Company Overview Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company dedicated to developing AAV vector-based gene therapies for rare central nervous system (CNS) diseases. The company’s proprietary platform harnesses tissue-specific promoters and a streamlined development process to address a range of inherited neurological disorders. Taysha’s lead programs are focused on monogenic diseases with high unmet medical need, and its approach aims to deliver durable, one-time treatments that can modify disease progression. The company’s pipeline includes TSHA-102 for Rett syndrome, TSHA-104 for GM1 gangliosidosis, TSHA-105 for giant axonal neuropathy and TSHA-118 for frontotemporal dementia (FTD) associated with progranulin deficiency. Each candidate employs an adeno-associated virus serotype optimized for CNS delivery and a promoter designed to drive expression in relevant neuronal or glial cell populations. Taysha has reported encouraging preclinical and early clinical data across several programs, demonstrating target engagement and favorable safety profiles in initial cohorts. Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies was established by a team of gene therapy veterans with backgrounds at leading academic institutions and biotechnology firms. The company has entered strategic collaborations with academic centers and contract development and manufacturing organizations to accelerate vector production and clinical supply. Taysha’s R&D operations leverage both in-house capabilities and external partnerships to support IND filings and ongoing trials in North America and Europe. Under the leadership of Chief Executive Officer Mona Sinha, a seasoned executive with extensive experience in translational research and drug development, Taysha continues to expand its footprint in the rare disease community. The management team includes experts in regulatory affairs, clinical operations and vector biology. Taysha is committed to engaging patient advocacy groups and shaping disease awareness, aiming to bring transformative gene therapies to underserved patient populations worldwide.AI Generated. May Contain Errors. Read More Taysha Gene Therapies Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreTSHA MarketRank™: Taysha Gene Therapies scored higher than 60% of companies evaluated by MarketBeat, and ranked 398th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingTaysha Gene Therapies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTaysha Gene Therapies has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Taysha Gene Therapies' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Taysha Gene Therapies are expected to decrease in the coming year, from ($0.35) to ($0.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Taysha Gene Therapies is -7.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Taysha Gene Therapies is -7.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTaysha Gene Therapies has a P/B Ratio of 6.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Taysha Gene Therapies' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.11% of the float of Taysha Gene Therapies has been sold short.Short Interest Ratio / Days to CoverTaysha Gene Therapies has a short interest ratio ("days to cover") of 8.8.Change versus previous monthShort interest in Taysha Gene Therapies has recently increased by 4.03%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTaysha Gene Therapies does not currently pay a dividend.Dividend GrowthTaysha Gene Therapies does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted16.11% of the float of Taysha Gene Therapies has been sold short.Short Interest Ratio / Days to CoverTaysha Gene Therapies has a short interest ratio ("days to cover") of 8.8.Change versus previous monthShort interest in Taysha Gene Therapies has recently increased by 4.03%, indicating that investor sentiment is decreasing. News and Social Media1.7 / 5News SentimentN/A News SentimentTaysha Gene Therapies has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Taysha Gene Therapies this week, compared to 3 articles on an average week.Search InterestOnly 7 people have searched for TSHA on MarketBeat in the last 30 days. This is a decrease of -42% compared to the previous 30 days.MarketBeat Follows7 people have added Taysha Gene Therapies to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Taysha Gene Therapies insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,062,500.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 3.78% of the stock of Taysha Gene Therapies is held by insiders.Percentage Held by Institutions77.70% of the stock of Taysha Gene Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Taysha Gene Therapies' insider trading history. Receive TSHA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Taysha Gene Therapies and its competitors with MarketBeat's FREE daily newsletter. Email Address TSHA Stock News HeadlinesTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)July 3, 2025 | globenewswire.comBeyond The Numbers: 10 Analysts Discuss Taysha Gene Therapies StockJuly 1, 2025 | benzinga.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.July 9 at 2:00 AM | Paradigm Press (Ad)Cantor Fitzgerald Reiterates “Overweight” Rating on Taysha (TSHA) for Positive TSHA-102 Clinical DataJune 29, 2025 | insidermonkey.comTaysha Gene Therapies Grants Stock Options to New Employees Under Inducement PlanJune 8, 2025 | nasdaq.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 6, 2025 | globenewswire.comTaysha Gene Therapies Releases TSHA-102 Clinical Program UpdatesJune 4, 2025 | insidermonkey.comRetail Buzz Surges Around Taysha Gene Therapies After Positive Rett Syndrome Trial DataJune 4, 2025 | msn.comSee More Headlines TSHA Stock Analysis - Frequently Asked Questions How have TSHA shares performed this year? Taysha Gene Therapies' stock was trading at $1.73 at the beginning of the year. Since then, TSHA stock has increased by 39.9% and is now trading at $2.42. How were Taysha Gene Therapies' earnings last quarter? Taysha Gene Therapies, Inc. (NASDAQ:TSHA) released its quarterly earnings data on Thursday, May, 15th. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.08). The business had revenue of $2.30 million for the quarter, compared to the consensus estimate of $1.48 million. Taysha Gene Therapies had a negative net margin of 1,201.08% and a negative trailing twelve-month return on equity of 104.93%. Read the conference call transcript. When did Taysha Gene Therapies IPO? Taysha Gene Therapies (TSHA) raised $125 million in an IPO on Thursday, September 24th 2020. The company issued 6,600,000 shares at $18.00-$20.00 per share. Goldman Sachs, Morgan Stanley and Jefferies served as the underwriters for the IPO and Chardan was co-manager. How do I buy shares of Taysha Gene Therapies? Shares of TSHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Taysha Gene Therapies own? Based on aggregate information from My MarketBeat watchlists, some other companies that Taysha Gene Therapies investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Alphabet (GOOG), Visa (V) and Walt Disney (DIS). Company Calendar Last Earnings5/15/2025Today7/09/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - GENERIC DRG Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TSHA CIK1806310 Webwww.tayshagtx.com Phone214-612-0000FaxN/AEmployees180Year Founded2020Price Target and Rating Average Price Target for Taysha Gene Therapies$8.20 High Price Target$11.00 Low Price Target$6.00 Potential Upside/Downside+238.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$89.30 million Net Margins-1,201.08% Pretax Margin-1,201.08% Return on Equity-104.93% Return on Assets-50.09% Debt Debt-to-Equity Ratio0.77 Current Ratio5.35 Quick Ratio5.35 Sales & Book Value Annual Sales$8.33 million Price / Sales62.36 Cash FlowN/A Price / Cash FlowN/A Book Value$0.35 per share Price / Book6.91Miscellaneous Outstanding Shares214,660,000Free Float206,548,000Market Cap$519.48 million OptionableOptionable Beta0.97 Social Links Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:TSHA) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Taysha Gene Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Taysha Gene Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.